President-elect Donald Trump has put forward a formal pick for the top spot at the U.S. Food and Drug Administration. | ...

For many biopharmas, it takes years of hard work to transition from being a clinical-stage drugmaker to a commercial one.

While Johnson & Johnson hopes to soon resolve more than 60,000 talc lawsuits with an $8 billion bankruptcy settlement in the ...

While president-elect Donald Trump has already made his leadership picks for the Department of Health and Human Services (HHS ...

For Big Pharma, recent headlines out of China suggest multinational drugmakers are facing their share of challenges in the ...

As the biopharma industry braces for a second term under President-elect Donald Trump, speculation is swirling around the ...

Every year, Fierce’s pharma, biotech, and medtech teams come together to spotlight some of the fiercest women in life s | ...

As a council of outside experts prepares to meet Thursday to discuss AstraZeneca’s Andexxa, the FDA has flagged “major safety ...

Few pharmaceutical products have taken the market by storm like Roche’s Vabysmo. | Interim results from a late-stage trial of ...

The new drug, Jazz Pharmaceuticals’ zanidatamab, has won an FDA accelerated approval for adults with previously treated ...

It was only last October that UCB’s up-and-coming immunology powerhouse Bimzelx first crossed the FDA finish line in ...

With Spanish plasma specialist Grifols turning down a potential multi-billion-dollar takeover bid, it’s likely back to the ...